$4.60
-0.05(-1.08%)
Mkt Cap $4M
$4.47
$58.40
52-Week Range
At a Glance
AI-generatedFY2025 saw Akari Therapeutics deliver narrowed operating and net losses via targeted cost reductions, with core focus on advancing its lead AKTX-101 pipeline program.
$4M
Market Cap
—
Revenue
—
Net Income
Employees8
Fundamentals
How The Business Makes Money
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Industry Biotechnology
Activity
Company Profile
CIK0001541157
ISINUS00972G2075
CUSIP00972G108
Phone44 20 8004 0270
Address75/76 Wimpole Street, London, W1G 9RT, GB
SEC EDGAR